Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) announced that the U.S. Food and Drug Administration (FDA)’s Gastrointestinal Drugs Advisory Committee voted 17 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

FBR Capital Remains on Sidelines with Intercept Pharmaceuticals (ICPT) Following FDA Panel BackingApril 8, 2016 9:51 AM Oppenheimer Reiterates $309 PT on Intercept Pharma (ICPT) Following FDA Panel BackingApril 8, 2016 8:25 AM Wedbush Reiterates Outperform, $423 PT on Intercept (ICPT) Following FDA Panel BackingApril 8, 2016 7:56 AM Panel Backing of OCA was Expected, Leerink Partners Says; Remains SidelinedApril 8, 2016 7:34 AM Intercept (ICPT) AdCom Couldn't Have Gone Better, Baird Says; Notes Gilead (GILD) Exec in the AudienceApril 8, 2016 7:02 AM Morgan Stanley Cuts Intercept (ICPT) to Underweight on Ocaliva Label/Launch Concerns, NASH Read-ThroughApril 8, 2016 6:56 AM Needham & Company Reiterates Buy on Intercept Pharma (ICPT) Following Positive FDA Panel Vote on Obeticholic AcidApril 8, 2016 6:53 AM Intercept Pharma (ICPT) to Resume Trading at 5:30 PM ETApril 7, 2016 5:05 PM FDA Advisory Committee Unanimously Recommends Accelerated Approval of Ocaliva™ (obeticholic acid) for the Treatment of PBCApril 7, 2016 5:00 PM Intercept Pharma's (ICPT) OCA wins FDA panel backing in PBCApril 7, 2016 3:49 PM Intercept Pharma (ICPT) Halted Ahead of FDA AdCom for OCAApril 7, 2016 7:10 AM